China-Israel Hyde: Going with "AI+Big Data", "Digital Intelligence Medical" explores the way to overcome hepatitis B

Beijing, September 23, 2021/PRNewswire/ - On September 19, Hyde, an artificial intelligence drug research and development platform, launched the "Looking for the Brave "Liver" Charity Program, which was launched on July 28 The first plan after the "Guardian Action" hepatitis B public welfare project is to seek free treatment for 3 hepatitis B patients across the country who are eager to be cured
.

On the same day, as a significant attempt by China-Israel Hyde to expand the whole chain of hepatitis B cure services, its self-developed family portable fingertip blood hepatitis B detector "exiaobai" (English name "EASY B") prototype was released
.

This instrument can not only provide patients with more convenient services, but also further solve the problem of privacy detection of hepatitis B patients

China-Israel Hyde home portable hepatitis B detector prototype "exiaobai" release site

Behind the efforts of China-Israel Hyde to conquer hepatitis B is the social background of many people "talking about liver discoloration" about hepatitis B.
Not only is it difficult to cure, but also because it is highly contagious.
Suffer discrimination
.

Cure hepatitis B is not only the cry of hepatitis B patients, but also the call of science and technology

However, for a long time, the research and development of hepatitis B drugs has been slow.
On the one hand, it is because of the difficulty of research and development.
On the other hand, compared with the global investment of tens of billions of dollars in the field of oncology, the research and development of hepatitis B drugs is considered "unpopular.
" "
.

In this way, overcoming hepatitis B has become an "old difficulty" problem, so that some practitioners compare it to the "long march" in drug development

The times call for responsibility
.

In 2019, China-Israel Hyde was co-founded by Roger Kornberg, Nobel Prize winner in Chemistry, Wang Shi, founder of Vanke Group, and Chen Mingjian, founder of Oriental Gaosheng, a well-known domestic investment bank in the field of health

Start with the end, don’t take the usual path

At present, there are about 100 million hepatitis B patients in China, of which about 30 million need treatment, and 7 million are facing the threat of deadly diseases such as liver cirrhosis, liver failure or liver cancer caused by HBV infection
.

There are nearly 1 million patients with liver cirrhosis and liver cancer caused by hepatitis B virus every year

"Looking for the brave "liver" charity charity plan is a small but firm step taken by China-Israel Hyde to solve this social medical problem
.

The plan will provide each patient with a full set of services for a year, worth about 100,000 yuan, of the "Rocket Rehabilitation Program" to help them get rid of the hepatitis B disease

What is the "Rocket Rehabilitation Program"? According to Li Yingying, chief scientist of China-Israel Hyde, the rocket rehabilitation program is based on the research and development of drugs, and based on AI technology, China-Israel Hyde tailors a personalized rehabilitation program based on the patient's individual information
.

According to this plan, after inputting the patient's genetic data, the matched hepatitis B pathogenesis, cure plan and targeted drug combination can be output with one click

Li Yingying emphasized that if you want to truly conquer hepatitis B, medicine is one of them, and personalized treatment plans are especially worth studying, because in the process of medication, individual biological characteristics are different, and there are often differences in efficacy
.

Under the situation of technological empowerment, the iterative update speed of treatment methods is staged a revolutionary breakthrough
.

In terms of drug research, the chairman of China-Israel Hyde, the chairman of Dongfang Gaosheng, and the chairman of Dongfang Lv said in an introduction: “In the past, the process of medical innovation was relatively long, but now the AI ​​+ big data model can help biomedicine.

Chairman of China-Israel Hyde and Dongfang Gaosheng

Judging from the results, the achievements of China-Israel Hyde are amazing
.
In January of this year, Li Yingying announced that four of its innovative drugs under the hepatitis B project have completed the pharmacobiological verification, and will start real-world research around the clinical research of the above four drugs
.
This means that it took only 90 days for these drugs to be screened from scratch to enter clinical research, which is 30 times faster than the development speed of traditional pharmaceutical companies that took at least three years
.

The basis for achieving this speed lies in the establishment of an AI network
.
China-Israel Hyde uses AI drug research technology to build a multi-dimensional AI network based on the combination of all listed safety drugs from the database of tens of thousands of drugs on the market, and human gene targets
.
Through this network, 100 compounds were found in the first phase, and then through biological verification, four drugs that entered the clinic were screened in only one month, and they were shown to be very effective in indicators of hepatitis B cure
.
Take one of these drugs as an example.
After 60 patients took it, the HBsAg (hepatitis B surface antigen) decreased by 81%.
This data exceeds the curative effect of all currently marketed nucleoside drugs
.

In addition to shortening the pre-clinical time from three years to 90 days, the subsequent clinical research time will also be greatly shortened
.
Under normal circumstances, clinical research needs to go through phases I, II, and III, which lasts as long as 5 to 8 years
.
The four drugs of China-Israel Hyde take the route of "old medicine and new use", and the safety of clinical phase I has been verified, and the following clinical phase II and III trials are expected to be combined
.

The good news is coincidentally.
On August 20th, China-Israel Hyde received an invention-creation patent entitled "Imidazolopyrimidine Compounds".
The drug involved in this patent is not only a new compound small molecule, but also significantly reduces HBV DNA.
, HBsAg
.
What's more exciting is that it took only 70 days from application to grant of this patent, creating another "quick miracle" in the history of China-Israel Hyde
.

The power of "digital wisdom medical treatment" is gradually emerging
.
"It is optimistic that we may only need about two years from pre-clinical to completion of clinical research to apply for a new drug, which is one-fifth of the traditional model
.
" Li Yingying said
.
In her view, this leapfrogging speed is the inevitable result of China-Israel Hyde insisting on the idea of ​​"starting with the end" and using data to guide drug development
.

"Our R&D path and traditional drug R&D are exactly the reverse
.
Traditional R&D starts from a target, and finds possible relevant indications from the target.
But if the target is selected wrong at the beginning, everything will follow.
They are all useless
.
Now we use AI algorithms to directly establish a connection relationship network from drugs and drug efficacy based on bioinformatics, genes, patient test data and other dimensions, which greatly reduces the cost of trial and error and uncertainty.
It saves time and is more controllable
.
" Li Yingying explained
.

"Subversive" innovation opens up new paths

Whether it is to use AI technology to "start with the end" to improve the efficiency of drug research and development, or to create a personalized rehabilitation program for patients, the development path of China-Israel Hyde's "digital wisdom medical" is very different from that of traditional pharmaceutical companies, and is full of "subversive" Innovation factor
.

This innovative gene is inseparable from the founder Chen Mingjian
.
Chen Mingjian is the founder of the domestic Bio-tech (biomedical) investment bank-Oriental Gaosheng.
He has been deeply involved in the field of pharmaceutical investment and mergers for many years.
He has experienced more than 20 years of domestic pharmaceuticals from generic drugs to the current generation of innovative drugs.
He has truly witnessed innovation.
Power
.

From investing in cross-industry to incubating his own company, Chen Mingjian said that there are "two points of persistence" that cannot be shaken: first, insisting on doing things that are truly socially beneficial to the domestic public.
Therefore, China-Israel Hyde does not blindly follow the trend of the popular tumor immunity track.
, But choose to gnaw on the “old problem” of hepatitis B; the second is to insist on taking a road that no one else has walked.
Traditional pharmaceutical factories have continued the research and development model for hundreds of years.
If they still follow the old road, it is meaningless
.

Chen Mingjian, founder of China-Israel Hyde and Dongfang Gaosheng

To innovate, to innovate from the source, today's booming AI technology has given Chen Mingjian an opportunity
.
He believes that the changes that AI technology brings to the development of traditional drugs may be like the revolution of Musk's electric vehicles to fuel vehicles, which is a "subversive" innovation
.
It is inspired by this that Eastern Gaosheng has incubated the world's leading artificial intelligence new drug research and development platform-China Israel Hyde
.
This pioneering work is not only derived from Chen Mingjian's keen investment vision, but also based on the deep accumulation of Oriental Gaosheng in the field of pharmaceutical innovation for many years
.

According to Qiu Sinian, Chairman of Orient Gaosheng and China-Israel Hyde, since 2016, Orient Gaosheng has no longer limited to pure financial business such as investment bank investment, but instead has accumulated power to incubate its own biomedical companies
.
Prior to this, they had served hundreds of pharmaceutical companies, spending 150,000 US dollars in consulting fees each quarter, inspecting innovative pharmaceutical companies on a global scale, and establishing a comprehensive target database
.
He pointed out: "Through a detailed investigation and research, we were able to distinguish what is truly valuable, and we have a deep understanding of the development process of an innovative pharmaceutical company, what capabilities and talents are needed, and we have achieved the goal of'no fight.
Unprepared battle'
.
"

In his view, the incubation of Hyde is the result of the deep integration of finance and industry
.
On the one hand, Dongfang Gaosheng’s endowment in the investment field can meet the capital needs of China-Israel Hyde for drug research and development; on the other hand, the investment experience accumulated in the past in serving the pharmaceutical industry has been transformed into the actual results of its own pharmaceutical industry
.
Not only that, but China-Israel Hyde’s AI pharmaceutical research model is also extremely advantageous in terms of cost investment
.

Qiu Si-nian said: “Since 2019, we have invested less than 100 million yuan in capital on China-Israel Hyde, all of which are self-owned.
Now four drugs have entered the clinic, and dozens of hepatitis B cures have been deployed.
The drugs are showing results one after another
.
"

Not only that, China-Israel Hyde has begun to expand the whole chain of hepatitis B cure services.
The self-developed home portable fingertip blood hepatitis B tester "exiaobai" recently launched is expected to become the first domestically marketed portable device that supports hepatitis B quantitative monitoring
.
This equipment is expected to enter the mass production stage in 2022.
After mass production, it is expected to be positioned as a thousand yuan machine, which is equivalent to the price of a patient going to the hospital for three tests
.

It is worth mentioning that China-Israel Hyde will also launch a digital patient management platform to facilitate patients to upload and manage their own data in real time
.
So far, China-Israel Hyde has been centering on the mission of “smearing the liver and brain and curing hepatitis B” and has blossomed in terms of drugs, services, testing equipment, and data management
.

On the long "long march" to conquer hepatitis B, China-Israel Hyde backed by Dongfang Gaosheng's financial endowment and its own AI drug research platform, the company has "subverted" the traditional drug research and development model, with the emergence of four new drugs and " The heavy launch of the Rocket Rehabilitation Program has reached a critical turning point in the Long March, and the future can be expected
.

Source: China-Israel Hyde